BIIB Q3 2019 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2019 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.6B+4.7% YoY

Gross Profit

$3.2B88.1% margin

Operating Income

$1.8B50.2% margin

Net Income

$1.5B42.9% margin

EPS (Diluted)

$8.39

QoQ Revenue Growth

-0.5%

Cash Flow

Operating Cash Flow

$1.7B

Free Cash Flow

$1.6B

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$27.5B

Total Liabilities

$13.5B

Stockholders' Equity

$14.0B

Cash & Equivalents

$2.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.6B	$3.4B	+4.7%
Gross Profit	$3.2B	$3.0B	+6.4%
Operating Income	$1.8B	$1.7B	+6.4%
Net Income	$1.5B	$1.4B	+7.0%

Revenue Segments

MS Product Revenues

$2.2B58%

SPINRAZA

$547M15%

Interferon

$530M14%

TYSABRI product

$484M13%

Geographic Segments

UNITED STATES

$1.7B59%

Non-US

$1.2B41%